cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.
teriparatide sun
sun pharmaceutical industries europe b.v. - teriparatíð - osteoporosis; osteoporosis, postmenopausal - kalsíumsterastasis - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
cinacalcet wh filmuhúðuð tafla 30 mg
williams & halls ehf. - cinacalcetum hýdróklóríð - filmuhúðuð tafla - 30 mg
venlafaxin medical valley forðatafla 150 mg
medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 150 mg
ibandronic acid wh filmuhúðuð tafla 50 mg
williams & halls ehf - ibandronate sodium monohydrate - filmuhúðuð tafla - 50 mg
reseligo (goserelin alvogen) vefjalyf í áfylltri sprautu 10,8 mg
zentiva k.s.* - goserelinum acetat - vefjalyf í áfylltri sprautu - 10,8 mg
venlafaxin medical valley forðatafla 300 mg
medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 300 mg
apomorfin pharmswed innrennslislyf, lausn 5 mg/ml
evolan pharma ab - apomorphin hýdróklóríð - innrennslislyf, lausn - 5 mg/ml
strefen honung & citron (strefen körsbär & mint) munnholsúði, lausn 16,2 mg/ml
reckitt benckiser healthcare (scandinavia) a/s - flurbiprofenum inn - munnholsúði, lausn - 16,2 mg/ml
emla (emla) krem 25+25 mg/g
aspen pharma trading limited - lidocainum inn; prilocainum inn - krem - 25+25 mg/g